Evidence map›Paper›PMID 41409263›Full record

ArticleDrug design, development and therapy2025

Detailed in silico Evaluation of WNV Proteins: Dynamic and Thermodynamic Insights into Doravirine as a Potential Multitarget Agent.

Antonio Curcio, Carlo Torti, Eugenia Quiros-Roldan, Stefano Alcaro, Anna Artese, Sparrow group

Abstract read
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Antonio CurcioDepartment of Health Sciences, University Magna Græcia, Catanzaro, 88100, Italy.ORCID 0009-0005-6818-5325
Carlo TortiInfectious Diseases Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy.
Eugenia Quiros-RoldanDepartment of Clinical and Experimental Sciences, Unit of Infectious and Tropical Diseases University of Brescia and ASST Spedali Civili Di Brescia, Brescia, Italy.
Stefano AlcaroDepartment of Health Sciences, University Magna Græcia, Catanzaro, 88100, Italy.
Anna ArteseDepartment of Health Sciences, University Magna Græcia, Catanzaro, 88100, Italy.ORCID 0000-0002-4638-7760
Sparrow group

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Purpose: The West Nile Virus (WNV) remains a global health problem, necessitating the identification of effective antiviral strategies. This study aimed to identify potential druggable targets for WNV and assess the repurposing of three FDA-approved antivirals - remdesivir, rilpivirine, and doravirine - through comprehensive in silico evaluations. Patients and Methods: Through molecular docking, molecular dynamics simulations (MDs), and Molecular Mechanics Generalized Born/Surface Area (MM-GBSA) free energy calculations, we assessed the stability, binding affinity, and thermodynamic profiles of the drug-protein complexes, focusing on the core protein, nonstructural protein NS3 serine protease, and two domains of nonstructural protein NS5: RNA-dependent RNA polymerase (RdRp) and methyltransferase (MTase). Results: Doravirine showed the most favorable and stable interactions across multiple targets. Specifically, it exhibited strong and persistent binding within the C-terminal tunnel and N-terminal hydrophobic pocket of the core protein, as well as at the KDKE motif and SAH-binding site of the NS5 MTase domain. Triplicate MD simulations and residue-level fluctuation analyses further confirm doravirine's stability and consistent interaction patterns in all binding sites, highlighting its potential as a promising candidate for WNV inhibition with multitarget activity. Conclusion: These findings provide in silico evidence supporting doravirine as a promising multitarget inhibitor of WNV, warranting further investigation for its repurposing for WNV treatment.

Indexed as

Antiviral AgentsPyridonesTriazolesWest Nile virusDibenzothiepinsHumansMolecular Docking SimulationMolecular Dynamics SimulationThermodynamicsAntiviral AgentsDibenzothiepinsdoravirinePyridonesTriazolesantiviral targetscomputational analysiscore proteinin silico evaluationMM-GBSAmolecular dockingmolecular dynamics simulationsnonstructural proteinsSiteMapWest Nile Virus

Identifiers

PMID41409263
PMCPMC12707240

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.